Given that peroxisome proliferator activated receptor gamma (PPARγ) is important in hepatic lipogenesis (Sharma and Staels, 2007), it has attracted considerable attention as a therapeutic target for NAFLD (Almeda-Valdés et al., 2009). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.